Sothema Acquires Ramo Pharm and Strengthens Its Wellness Division
Moroccan Pharmaceutical Group Sothema Announces Acquisition of Ramo Pharm
On October 28, 2026, Moroccan pharmaceutical group Sothema announced the signing of an agreement to acquire 100% of the capital of Ramo Pharm, a Moroccan company specialized in dietary supplements. This strategic move aims to strengthen Sothema’s presence in the wellness and public health market.
Through this acquisition, Sothema intends to diversify its activities and develop a new sector focused on Wellness & Consumer Health, complementing its core operations in pharmaceuticals, specialized products, and dialysis solutions.
Ramo Pharm: A Moroccan Player in Dietary Supplements
Founded in 1999 and based in Casablanca, Ramo Pharm specializes in the development and marketing of dietary supplements, primarily distributed through pharmacies. The company boasts a portfolio of brands that includes Enrouex, ZENmag, Toudex, Hivernex, and Matervit.
Its products address several health and wellness segments, particularly immune support, sleep enhancement, stress management, and women’s health.
The integration of Ramo Pharm will enable Sothema to solidify its position in a market where consumer health products are increasingly central to the diversification strategies of pharmaceutical groups.
Sothema Focuses on a New Wellness & Consumer Health Sector
With this acquisition, Sothema plans to establish a dedicated sector for wellness and public health that complements its existing activities. This focus will allow Sothema to expand its product portfolio and strengthen its presence across various health market segments.
The group also intends to leverage its international distribution networks to support Ramo Pharm’s development and facilitate the expansion of its brands beyond the national market.
This strategy is built on the complementarity between Ramo Pharm’s expertise in dietary supplements and Sothema’s industrial and commercial capabilities. However, specific details regarding this expansion have not been disclosed in the announcement.
Acquisition Subject to Regulatory Approvals
The transaction involves acquiring the entirety of Ramo Pharm’s capital. Its finalization, however, is contingent upon compliance with applicable regulatory procedures, notably the approval of the Competition Council.
The financial details of the operation have not been disclosed.
This acquisition marks a new phase in Sothema’s diversification strategy. By strengthening its activities in dietary supplements and public health, the group aims to consolidate its position in the Moroccan wellness market while opening new avenues for development through its international distribution networks.
